Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature.

Journal: Frontiers in medicine

Volume: 7

Issue: 

Year of Publication: 

Affiliated Institutions:  Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, Palermo, Italy. Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy. Department of Cancer Epidemiology and Prevention Research, Cancer Control Alberta, Alberta Health Services, Calgary, AB, Canada. Department Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy. Emergency Medicine (A&E) - Asl - H Santa Corona, Pietra Ligure and First Aid, H Santa Maria Misericordia, Albenga, Italy. Primary Care Department, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy. Italian Agency for Development Cooperation, Khartoum, Sudan. Exercise and Mental Health Laboratory, Shenzhen University, Shenzhen, China. School of Health Sciences, Institute of Mental Health Sciences, Ulster University, Newtownabbey, United Kingdom. Research and Innovation Department, The Queen Elizabeth Hospital Foundation Trust, King's Lynn, United Kingdom. The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, United Kingdom. Faculty of Sport Sciences, University of Murcia, Murcia, Spain.

Abstract summary 

The aim was to investigate the effectiveness of glucocorticoid therapy in patients with COVID-19. A systematic search of the literature across nine databases was conducted from inception until 15th March 2020, following the PRISMA guidelines. Patients with a validated diagnosis of COVID-19 and using corticosteroids were included, considering all health outcomes. Four studies with 542 Chinese participants were included. Two studies reported negative findings regarding the use of corticosteroids in patients with COVID-19, i.e., corticosteroids had a detrimental impact on clinical outcomes. One study reported no significant association between the use of corticosteroids and clinical outcomes. However, one study, on 201 participants with different stages of pneumonia due to COVID-19, found that in more severe forms, the administration of methylprednisolone significantly reduced the risk of death by 62%. The literature to date does not fully support the routine use of corticosteroids in COVID-19, but some findings suggest that methylprednisolone could lower mortality rate in more severe forms of the condition.

Authors & Co-authors:  Veronese Nicola N Demurtas Jacopo J Yang Lin L Tonelli Roberto R Barbagallo Mario M Lopalco Pierluigi P Lagolio Erik E Celotto Stefano S Pizzol Damiano D Zou Liye L Tully Mark A MA Ilie Petre Cristian PC Trott Mike M López-Sánchez Guillermo F GF Smith Lee L

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. (2020) 92:418–23. 10.1002/jmv.25681
Authors :  15
Identifiers
Doi : 170
SSN : 2296-858X
Study Population
Male,Female
Mesh Terms
Other Terms
ARDS;COVID-19;SARS-Cov-2;coronavirus;corticosteroids;methylprednisolone;pneumonia
Study Design
Study Approach
,Systemic Review
Country of Study
Publication Country
Switzerland